The idea being tested is recognizing the Belmont Report's three guiding principles and how they shape ethical research. The three guiding principles are respect for persons, beneficence, and justice. Respect for persons centers on treating individuals as autonomous agents and providing extra protection to those with diminished autonomy. In practice this shows up in the informed consent process, ensuring people understand what they are agreeing to, and safeguarding privacy and confidentiality. Beneficence calls for maximizing potential benefits while minimizing possible harms. Researchers weigh risks and benefits, design studies to reduce risk, monitor safety, and ensure that the anticipated benefits justify any burdens placed on participants. Justice focuses on fair distribution of research burdens and benefits. This means choosing subjects in a way that is equitable, avoiding exploitation of vulnerable groups, and ensuring that the benefits of research are accessible to those who contribute to it. In practice, these principles guide ethics review, the content and process of informed consent, risk–benefit analysis, and decisions about who is recruited. If anything else is mentioned, privacy and consent relate to the first principle, and nonmaleficence is a related idea in bioethics but is not one of the Belmont Report’s three principles.

In evidence-based practice, clinical expertise serves as the bridge between research findings and the individual patient’s situation. It involves using professional judgment to interpret what the research means for a specific patient, considering factors like comorbidities, feasibility, risks, and practicality, and then applying that evidence in a way that fits the patient’s values and circumstances. This is why the statement that best describes its role is that it helps interpret and apply research within the patient’s values and circumstances. This isn’t the sole SAMPLEbasis for care, nor is it optional, and it isn’t meant to be replaced by patient values alone. Patient values are the other essential component, but clinical expertise is what lets you translate the general evidence into a personalized, workable plan.

The concept being tested is Evidence-Based Practice. It describes using the best available evidence from research together with the clinician’s own expertise and the patient’s values and preferences to guide clinical decisions. In practice, this means asking a focused question, finding high-quality evidence, critically appraising it, and then applying it within the context of what the patient values and what the clinician knows from experience, followed by evaluating outcomes. This integrative approach distinguishes Evidence-Based Practice from simply relying on a single study design or on what patients or clinicians prefer without evidence. The other options don’t capture this integrative decision-making process: a randomized trial is a study method, publication bias refers to selective reporting, and barriers are obstacles to implementing evidence.

The main idea is how confident we are in detecting a real effect. Power is the probability of correctly rejecting a false null hypothesis, while Type II error is the probability of failing to reject a false null. They are connected by power = 1 minus beta, where beta is the Type II error rate. So when you increase power, beta decreases, meaning the chance of missing a true effect goes down. Methods to raise power include larger sample size, a larger true effect, or a design that improves sensitivity, all of which help detect real differences without necessarily inflating false positives. If you adjust alpha upward, you might increase Type I error, but the direct relationship between power and Type II error is inverse: higher power means lower Type II error. Therefore increasing power reduces the probability of a Type II error.